Abstract
Wei, L, Wang, X, Luo, M, Wang H, Chen H, Huang C (2021) The PAD4 inhibitor GSK484 enhances the radiosensitivity of triple-negative breast cancer. Human & Experimental Toxicology 40(7): 1074–1083. DOI: 10.1177/0960327120979028
In this article, the author mistakenly used the incorrect Figure 1D in the published version. The revised and corrected Figure 1D is presented here: Effects of GSK484 on TNBC cell proliferation and radiosensitivity. (A) The IC50s of GSK484 in MDA-MB-231 and BT-549 cells (B) Survival fraction curves of MDA-MB-231 and BT-549 cells after treatment of GSK484 or IR. (C) Numbers of clones at 14 d after IR in TNBC cells treated with and without GSK484. (D) Cell migration and invasion were detected by transwell assays. (E) The protein levels of MMP2 and MMP9 were examined by western blot analysis. *P < 0.05.